Efficacy and safety of finerenone in non-diabetic patients with IgA nephropathy
Abstract
BACKGROUND: Finerenone has been proven to have cardiovascular and renal protective effects on chronic kidney disease associated with type 2 diabetes. However, the therapeutic effect of finerenone on IgA nephropathy (IgAN) without diabetes remains unclear. METHODS: A retrospective analysis was conducted on patients with primary IgAN who received standard treatment between September 2023 and June 2025. The patients were divided into the finerenone and control groups based on whether finerenone was used. The primary outcomes were the renal complete response (CR) rate (
Fields of Study & Subjects
Renal Diseases and Glomerulopathies
Pediatric Urology and Nephrology Studies
Urinary Bladder and Prostate Research
Publication details
- Journal / source
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Volume
- 41
- Issue
- 8
- Pages
- 1508–1519
- Publication date
- 5 February 2026
- Language
- EN